Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/33090
Title: Long-term outcomes of modern multidisciplinary management of sinonasal cancers: The M. D. Anderson experience.
Austin Authors: Bahig, Houda;Ehab, Hanna Y;Garden, Adam S;Ng, Sweet Ping ;Frank, Steven J;Nguyen, Theresa;Gunn, Gary B;Rosenthal, David I;Fuller, Clifton D;Ferrarotto, Renata;Bell, Diana;Su, Shirley;Phan, Jack
Affiliation: Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.;Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada.
Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Radiation Oncology
Olivia Newton-John Cancer Wellness and Research Centre
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Issue Date: Jul-2023
Date: 2023
Publication information: Head & Neck 2023-07; 45(7)
Abstract: To report long-term outcomes of modern radiotherapy for sinonasal cancers. A retrospective analysis of patients with sinonasal tumors treated with intensity-modulated radiotherapy or proton therapy. Multivariate analysis was used to determine predictive variables of progression free survival (PFS) and overall survival (OS). Three hundred and eleven patients were included, with median follow-up of 75 months. The most common histologies were squamous cell (42%), adenoid cystic (15%), and sinonasal undifferentiated carcinoma (15%). Induction chemotherapy was administered to 47% of patients; 68% had adjuvant radiotherapy. Ten-year local control, regional control, distant metastasis free survival, PFS, and overall survival rates were 73%, 88%, 47%, 32%, and 51%, respectively. Age, non-nasal cavity tumor site, T3-4 stage, neck dissection, and radiation dose were predictive of PFS, while age, non-nasal cavity tumor site, T3-4 stage, positive margins, neck dissection, and use of neoadjuvant chemotherapy were predictive of OS. There was a 13% rate of late grade ≥3 toxicities. This cohort of patients with sinonasal cancer treated with modern radiotherapy demonstrates favorable disease control rate and acceptable toxicity profile.
URI: https://ahro.austin.org.au/austinjspui/handle/1/33090
DOI: 10.1002/hed.27381
ORCID: 0000-0001-9508-0602
0000-0001-7926-2641
0000-0001-6517-7884
0000-0002-5264-3994
0000-0002-3561-215X
0000-0002-3903-8204
0000-0001-5977-6004
Journal: Head & Neck
Start page: 1692
End page: 1703
PubMed URL: 37165701
ISSN: 1097-0347
Type: Journal Article
Subjects: IMPT
IMRT
SCC
SNUC
VMAT
conformal radiotherapy
head and neck cancer
intensity modulated radiation therapy
paranasal sinus cancer
proton therapy
radiation therapy
radiotherapy
sinonasal tumors
Paranasal Sinus Neoplasms/pathology
Nose Neoplasms/pathology
Maxillary Sinus Neoplasms/pathology
Radiotherapy, Intensity-Modulated/methods
Appears in Collections:Journal articles

Show full item record

Page view(s)

24
checked on Nov 20, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.